The fears that the downward spiral of the capital markets during the financial crisis that occurred in 2008 would be repeated in the wake of last week's "Black Monday" are, for the time being, in the rearview mirror. Read More
In biotech, figuring out how to take cool-sounding science and translate it both through a clinical development pathway and into commercial applications have always been the challenges du jour. Read More
Data from an ongoing phase I trial turned up even better than many expected with ALN-PCS, the subcutaneously given RNAi proprotein convertase subtilisin/kexin type 9 (PCSK9) blocker in the works by Alnylam Pharmaceuticals Inc. and The Medicines Co. for lowering LDL-C. Read More
Breaking the immune system's tolerance to cancer cells has been the biggest breakthrough in cancer therapies in recent years, but to date the approach is successful only in a minority of patients. Read More
HONG KONG – Standing out of a crowd of more than 200 next-generation sequencing (NGS) product developers in China, a 20-month-old company raised ¥150 million (US$23 million) in a follow-up series A financing and struck a partnership deal with U.S. genomics leader Illumina Inc. Read More
The Health Resources and Services Administration on Friday released a new draft of guidance for hospitals and other health care organizations regarding the 340B section of the Public Health Service Act, a drug pricing program intended "to permit covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services." Read More
In targeted cancer therapies, dramatic response rates are usually rapidly followed by resistance. In principle, however, that resistance might be forestalled by rational combination therapies that preemptively cut off tumors' escape routes. Read More
